Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 3,700 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 3,700 shares of Pharvaris stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $30.08, for a total value of $111,296.00. Following the completion of the transaction, the insider owned 56,450 shares of the company’s stock, valued at approximately $1,698,016. This represents a 6.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anne Lesage also recently made the following trade(s):

• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $580,992.00.
• On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $656,642.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Trading Down 5.1%

PHVS stock opened at $29.44 on Friday. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -8.74 and a beta of -2.34. Pharvaris N.V. has a 12-month low of $14.59 and a 12-month high of $31.14. The business’s 50-day moving average is $27.62 and its 200 day moving average is $26.03.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). As a group, equities analysts forecast that Pharvaris N.V. will post -3.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen cut Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday, April 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six?figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near?term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ?$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ?$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ?$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new position in Pharvaris during the third quarter worth $1,943,000. Patient Square Capital LP lifted its stake in Pharvaris by 41.4% during the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after purchasing an additional 101,098 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in Pharvaris by 735.1% during the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after purchasing an additional 118,994 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock valued at $676,000 after acquiring an additional 23,743 shares in the last quarter. Finally, General Atlantic L.P. raised its stake in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.